Ubix Therapeutics Granted Green Light from FDA for Initial Clinical Trial of Oral Drug UBX-303-1, a BTK Inhibitor Aimed at Treating Resistant B-Cell Cancers.

NKGen Biotech, Inc. declares the commencement of treatment in its initial participant within a Phase 1/2a Study using its own SNK01, aimed for moderate Alzheimer's Disease.

NeuroBo Pharma has filed an Investigational New Drug request with the FDA, seeking approval to commence a Phase 1 trial on compound DA-1726 aimed at combating obesity.

Clover Biopharmaceuticals reports positive initial findings from a phase I trial evaluating SCB-219M, an advanced bispecific Fc-fusion TPO-RA protein developed with CHO cell systems, focusing on safety, efficacy, and pharmacokinetics.

Innovent and Xuanzhu Initiate Joint Study Exploring Dual Treatment Approach with Sintilimab (PD-1 Blocker) Plus a New ADC Drug for Progressive Solid Cancers in China.

Elpiscience has partnered with Astellas Pharma through a fresh research and licensing deal to develop innovative dual-targeting macrophage engagers.

Cytokinetics Reveals Encouraging Outcomes in Key Phase 3 Study Called SEQUOIA-HCM, Evaluating Aficamten for Obstructive Hypertrophic Heart Condition.

Oncternal Therapeutics has released new information regarding its ongoing early to mid-stage clinical trial of ONCT-808, a CAR T therapy aimed at ROR1, for individuals facing recurring or hard-to-treat aggressive B-cell lymphoma.

RayzeBio's RYZ101 targets SSTR2, often overexpressed in GEP-NETs and extensive stage small cell lung cancer.

Coherus has revealed that UDENYCA ONBODY™, an innovative and advanced technology for administering pegfilgrastim-cbqv, has received authorization from the FDA.

Chugai Pharma announced preclinical results for their antibody, DONQ52, published in Nature Communications.

LegoChem Biosciences announced a licensing deal with Janssen Biotech to develop and market LCB84, a Trop2-targeted antibody-drug conjugate.